CEL-SCI's CEO Says H1N1 Flu Drug Candidate Could Propel Company Onto World Stage

LOS ANGELES, CA, Sep 18 (MARKET WIRE) --
BioMedReports.Com, the news portal which covers Wall Street's biomedical
sector and delivers financial and investment intelligence to a community
of highly informed investors, has issued a transcript of their interview
with CEL-SCI Corporation's CEO, Geert Kersten.

CEL-SCI Corporation's (NYSE Amex: CVM) just received FDA approval to
proceed with a clinical trial of its H1N1 flu drug candidate, testing its
effect on white blood cells of patients who are hospitalized. The biotech
firm said it is working on the next phase of the study and is preparing
the drug's follow-up regulatory application.

"You have to consider that the 'bad' evolution of this virus is most
likely to happen outside of this country," says Kersten. "That's where
you're going to get re-assortment. We don't know what those death rates
could be, but what you have from the current virus is high
transmissibility in warm weather which has not been seen before in any
other flu virus. If it picks up something nasty from another virus and
that person gets on a plane, well then suddenly CEL-SCI could be the most
important company in the world because there will be no one else who has
done any work on this at all. Everyone would come to us."

The complete transcript is available now at BioMedReports.Com:

http://biomedreports.com/component/content/article/56-top-leading-news/10089-ceo
other-countries-may-also-want-cel-scis-h1n1-treatment.html

Biotech investors interested in accessing the news portal's complete
database of clinical trials and upcoming FDA decisions can access that
information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

For more biomedical sector and investment news go to
http://BioMedReports.com

Contact:
Mike Havrilla
Managing Editor
BiomedReports.Com
e-mail: Email Contact
Tel: +1 323 472 4480
Fax: +1 888 210 3556

Copyright 2009, Market Wire, All rights reserved.

-0-